NCT06283966: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 3 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06283966 |
|---|---|
| Title | A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 21, 2024 |
| Completion date | March 7, 2028 |
| Required reporting date | March 7, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |